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The standardization of cannabis doses is a priority for research, policy-making, clinical
and harm-reduction interventions and consumer security. Scientists have called for
standard units of dosing for cannabis, similar to those used for alcohol. A Standard
Joint Unit (SJU) would facilitate preventive and intervention models in ways similar
to the Standard Drink (SD). Learning from the SD experiences allows researchers to
tackle emerging barriers to the SJU by applying modern forecasting methods. During a
workshop at the Lisbon Addictions Conference 2019, a back-casting foresight method
was used to address challenges and achieve consensus in developing an SJU. Thirty-two
professionals from 13 countries and 10 disciplines participated. Descriptive analysis
of the workshop was carried out by the organizers and shared with the participants
in order to suggest amendments. Several characteristics of the SJU were defined: (1)
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core values: easy-to use, universal, focused on THC, accurate, and accessible; (2) key
challenges: sudden changes in patterns of use, heterogeneity of cannabis compounds
as well as in administration routes, variations over time in THC concentrations, and of
laws that regulate the legal status of recreational and medical cannabis use); and (3)
facilitators: previous experience with standardized measurements, funding opportunities,
multi-stakeholder support, high prevalence of cannabis users, and widespread changes
in legislation. Participants also identified three initial steps for the implementation of a
SJU by 2030: (1) Building a task-force to develop a consensus-based SJU; (2) Expanded
available national-level data; (3) Linking SJU consumption to the concept of “risky use,”
based on evidence of harms.
Keywords: cannabis, standard units, harm-reduction, risky use, prevention
INTRODUCTION
After tobacco and alcohol, cannabis is the most widely used
psychoactive substance worldwide. Societies are experiencing a
normalization of its use, especially among youth (1) as illustrated
by the growing phenomena of coffeeshops and cannabis social
clubs (2). Cannabis policy is shifting worldwide as the supply is
moving from an unregulated (illicit) market to an open market
for an “ordinary commodity” (e.g., in Canada, Uruguay and
several states within the US). Observing that public opinion on
the legal status of cannabis in Europe is also changing, European
countries likely will not be an exception to this trend over the
coming years. This changing context (i.e., in social perceptions
and in legal context in some countries) aligns cannabis use in
high-income countries more closely with alcohol or tobacco
than to currently illegal drugs. A transition to legal, regulated
access will require new prevention and harm-reduction strategies
to minimize adverse effects as cannabis becomes more widely
available (3). However, evidence also points to higher THC
concentration in cannabis products during the last decade,
which is believed to be associated with an increased risk of
acute, and chronic health problems, especially in adolescents
(4). Additionally, the National Institute on Drug Abuse has
already expressed plans to “explore the possibility of constructing
a standardized dose similar to that for alcohol (the standard
drink) and tobacco (a cigarette) [. . . for cannabis] for researchers
to employ in analyzing use and [. . . ] for users to understand
their consumption (5).” Learning from the history of measuring
standard units, i.e., alcohol and tobacco, could facilitate public
health, research and clinical professionals to navigate this
new context more successfully and prevent errors from being
repeated. During the 1980s and 1990s, several countries reached
a national consensus defining their Standard Drink (SD) (6).
Researchers conducted field tests in several countries to grow
comparative evidence and adapt prevention efforts to the cultural
characteristics of the country (7). However, most countries did
not re-validate the SD with the field test (8). As a result, there
are large differences between countries in defining SD, due
to the fact that some are based on national consensus while
others derive from experimental research, making useful cross-
country comparison, policy analysis and prevention efforts more
difficult. Nonetheless, despite its limited accuracy, the SD has
advanced the alcohol public health field considerably: the SD
provides clinicians, public health specialists, policy makers, and
researchers with a common tool for assessing alcohol use and
implementing programs from early identification of risky use (9)
to monitoring consumption in harm-reduction (10).
Other relevant instruments for assessing alcohol use were
based on the SD [AUDIT (11), ISCA (12), AUDIT-C (13),
HRAR (14)] and are widely implemented globally. Screening
and Brief Interventions (SBI) programs, make use of these
instruments, are cost-effective in 24 out of 28 EU countries and
cost-saving in 50% of countries (15). Learning from practical
experiences in the alcohol field and the development and use of
SD, the following should be essential characteristics in developing
a Standard Joint Unit (SJU): (1) a high degree of evidence-
based consensus on equivalence between countries; (2) high
accuracy (providing a faithful representation of real doses);
(3) taking into account less common routes of administration
(cannabis is consumed in more varied ways than alcohol or
tobacco); (4) built in monitoring of changes in patterns of use
and chemical composition. Having said this, many peculiarities
of cannabis use present challenges in the development of
standard units for cannabis, among these are: different routes
of administration (smoking, vaping, edible), concurrent use
with other substances (e.g., tobacco, alcohol), heterogeneity
of quantities or interactions among different cannabinoids
(THC/CBD) (16). Standard units for cannabis, based on a fixed
dose of THC, have the potential to address some of these
challenges (16). What constitutes a SJU is important to consider.
Currently, studies have gathered evidence on typical joints in
Australia (140mg cannabis/joint), Spain (250mg of hashish or
cannabis plant/joint and translating into 7mg THC/joint), The
Netherlands (260mg cannabis/joint), UK (140mg cannabis/joint
and 380mg cannabis/joint), USA (660mg cannabis/joint vs.
580mg cannabis/joint vs. 700mg cannabis/joint) (17–24). Only
the Spanish study reported milligrams of THC in a typical joint.
Although a commendable start, these studies were heterogeneous
regarding both methods (real/simulated cannabis, ecological/lab
studies, etc. . . ) and results, even within countries. In the
European Web Survey on Drugs (25), the EMCDDA also asks
about usual amount consumed for herbal cannabis and cannabis
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resin. The rapid growth of research in this field also means
that reaching a consensus on SJU research methodologies to
support clinical implementation is an urgent issue. In order to
advance this area, we organized a workshop, as part of the Lisbon
Addictions Conference 2019, with experts in different disciplines
(sociology, psychology, public health, basic and clinical research,
psychiatry) and with the following objectives: (1) to reflect on
the challenges to reaching a consensus on an operative SJU; (2)
to reflect on opportunities and facilitators to achieving an SJU;
(3) to propose different trajectories to achieve the main goal:
implementation of a European SJU by the year 2030; and (4)
to reach a minimum-level consensus on the first step toward
achieving a SJU. The expected outputs were: (1) consensus on the
first-steps toward achieving an SJU; and (2) a preliminary annual
roadmap to develop a SJU by the year 2030.
METHODS
The Back-Casting Exercise (BCE)
An operational definition of a BCE is “a scenario technique where
normative targets or unwanted outcomes are defined by a group
for the purpose of formulating ways in which such goals can be
achieved or avoided” (26). Participants in back-casting exercises
do not predict the future, but rather choose the desirable future
and work backwards to define the steps to achieve that goal (26).
Back-casting is a prospective method in the context of foresight
methodologies. Foresight methodologies are “frameworks for
making sense of data generated by structured processes to think
about the future” (27). A back-casting exercise is useful when
(28, 29):
1. the problem is complex, persistent, and predominant.
2. change is very necessary.
3. sustainability of the solution is relevant.
4. long-term planning (at least 5 years) is needed.
5. the results of the exercise could impact multiple stakeholders
and could empower the participants in the exercise.
The organizers pre-defined the desirable future in 2030 based
on their professional expertise in the alcohol and cannabis areas
(see Figure 1). The contrast between desirable future and current
scenario (see below) is the starting point for the workshop
discussions. The current scenario was defined as:
• The populations at risk of suffering cannabis-related health
problems are not well-identified.
• The assessment of cannabis use patterns is usually based on
frequency of use (e.g., days) only.
•A clear public health message about “howmuch is too much”
does not exist because low-risk use is not well-defined.
• The prevalence of risky use (in different populations) is
unknown due to lack of risk level definitions.
• Evidence-based practices to reduce cannabis-attributable
harms (i.e., SBIRT) are not implemented.
Participants
A total of thirty-two experts attended the workshop. Participants
were scholars and practitioners from a range of disciplines: basic
research (n = 1), pharmacology (n = 1), neuroimaging (n = 3),
social sciences (n = 3), psychology (n = 3) and other clinical
research (n = 10), public health (n = 4), epidemiology (n =
4), law and criminology (n = 2). Furthermore, one cannabis
industry representative participated. Experts were divided into
five transdisciplinary groups. Participants came from several
different countries (in descending order of number): UK (n =
7), Spain (n = 5), Portugal (n = 5), The Netherlands (n = 3),
USA (n = 2), Germany (n = 2), Australia (n = 2), Belgium (n =
1), Hungary (n = 1), Poland (n = 1), Cyprus (n = 1), Israel (n
= 1) and Canada (n = 1). Participants had either pre-registered
for the back-casting workshop (n = 21) or arrived to participate
spontaneously (n = 11) (these participants were admitted until
all available seats were occupied). The workshop was comprised
of both academics invited, based on their expertise (n = 17); and
participants from the conference (n= 15) (see Figure 2).
In order to facilitate the workshop dynamics and facilitate
a smoother running of the exercise, those who had previously
registered received a 3-page background document on the SJU
concept, the back-casting method, and relevant key references,
along with the following advice: (1) An absolute consensus is
not expected. Please focus on achieving minimum consensus; (2)
Try to find cause-effect relationships; (3) Try to focus on one
future desirable scenario; and (4) Do not attempt to predict the
future but rather consider the desirable future. The exercise was
led by two clinician scientists, both with extensive experience
in participatory workshops (AG and HLP). Three researchers –
two of them with ample experience in participatory processes –
collaborated in the design, preparation, and deployment of the
workshop, and the analyses of the results (SM, EC and FB). These
five experts conceptualized, designed and developed the exercise.
Procedure (90min)
We prepared and set up the back-casting exercise in the following
steps (adapted from “STD back-back casting approach” and
Wilson et al. 2006) (30):
Step 1 (10min): Introduction - The first part of the session was
dedicated to explain the rationale underlying the workshop, its
objectives, methodology and expected outcomes. Afterwards,
a description of the current scenario and a future desirable
scenario was presented to the participants, with sufficient time
reserved for questions or amendments to both current and
future scenarios.
Step 2 (20min): Prioritizing relevant elements - Activity 1
was explained and participants were allocated to small multi-
disciplinary groups (6–7 people) for the first part. They had
three lists of elements referring to the SJU: (i) challenges, (ii)
facilitators, (iii) values (see Supplementary Tables 1–3). The
lists included a definition for each concept. Participants could
propose new items if they considered that the definition was
not accurate or if a concept was missing. Each small group
was instructed to choose by consensus the five most relevant
concepts from each list. In the second part of the exercise the
whole workshop group worked together and voted on each
concept for relevance, after hearing the outcomes of previous
consensus discussions.
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FIGURE 1 | Hypothetical desirable future in 2030, used to guide the back-casting workshop.
Step 3 (30min): Back-cast trajectories - Activity 2 from future
to present was performed by each small group (n = 5, of 6–
7 participants each). The groups focused on a specific key
element of the bigger desirable future scenario, and each had a
card with the description of this element (group 1: Primary
care; group 2: Prevention; group 3: Cannabis users; group
4: Epidemiology; group 5: Research). Using a pre-designed
canvas, each group deconstructed the route toward the end-
point of the specific scenario element in 2030, starting in
2020 (see Supplementary Table 4). At the end of this exercise,
the results were briefly shared with the other members of
the workshop.
Step 4 (10min): Defining key events - this slot was
allocated to a discussion across the groups of cornerstones,
milestones, and first steps based on the reflection
during the exercise and the professional background of
the participants.
Summary (5min): The exercise ended with a brief summary
given by one of the participants (TPF), as rapporteur of the
group. The participant was one of the coordinators of the
preconference workshop “International Cannabis Toolkit,” in
order to link these events. (https://www.lisbonaddictions.eu/
lisbon-addictions-2019/side-events). The context of the FuturiZe
Project and the Lisbon Addictions Conference is explained in the
Supplementary Material.
Analyses
Descriptive analysis of the workshop was carried out by
the organizers and shared with the participants in order to
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FIGURE 2 | Recruitment process of participants in the workshop.
suggest amendments. No quantitative or qualitative analyses
were conducted.
Ethical issues: Under Spanish law, no ethical approval was
required for this study in which the data is expert opinion.
RESULTS
Future Desirable Scenario
The workshop participants did not raise any modifying
comments or objections on the desirable future scenario
(i.e., implementation of a SJU based on consensus) as
proposed by the organizers, and approved unanimously it
(see Figure 1).
Defining Values, Challenges and
Facilitators (Supplementary Tables 1–3
Respectively)
The five most highly voted defining values associated with
SJU were “easy-to-use” (straightforward, clear instructions and
simple to use correctly, 100%), “universal” (appropriate for or
adjustable to all settings/contexts, 100%), “accounts for THC”
(quantity of use register will only include THC, 80%), “accurate”
(providing a faithful representation of someone or something,
60%) and “accessible” (easily understood or appreciated, 60%).
The five most highly voted challenges were: “sudden changes
in patterns of use” (quick and unexpected changes in the
behavior of cannabis users which impact the validity/accuracy
of the SJU, 100%), “heterogeneity of cannabis compounds”
(diversity in content/composition, 80%), “heterogeneity of
THC concentration” (diversity on THC content for the same
grams of herbal or resin, 80%), “heterogeneity in routes of
administration” (diversity in routes of administration (smoking,
vaping, edible, etc.), 60%) and “laws” (legal status of marijuana
(e.g., possession being criminal offense) in many countries, 60%).
“Synthetic cannabinoids” were proposed as a separate additional
challenge by one participant, but this challenge was included
by consensus of participants in the category of “heterogeneity
of cannabis compounds.” The six most highly voted facilitators
were: “previous experience in other standard measurements”
(Learning about the limitations and strengths of standardization
of typical dose and operational definitions of risky use in
tobacco or alcohol, 100%),” funding opportunities available”
(money provided, especially by an organization or government,
for drug research is now addressed to the area of cannabis,
80%), “cannabis users’ support” (organized or non-organized
users whose messages are partially or totally in line with the
objectives of the SJU 80%), “policy-makers’ support” (roadmap
or agenda of policy-makers is partially or totally in line with
the objectives of SJU, 60%), “high prevalence of use” (health
topic becomes more prevalent and more mainstream,60%),
“depenalization, decriminalization and legalization in many
countries” (changes in laws regarding cannabis which facilitate
research into cannabis and the implementation of solutions
conducive to harm-reduction approaches, 60%). “New advances
in laboratory studies” were proposed and accepted as an
additional facilitator, which was voted on by a majority of the
groups (60%).
Back-Casting Trajectories (From 2030 to
2020) and Milestones
(Supplementary Table 4)
The most salient milestones reported by participants were: (1)
negotiate and engage the stakeholders as an ongoing process;
(2) set of scenarios (options) to discuss the analytical phase;
(3) guidelines for using the SJU (setting, protocols, etc.); (4)
definition and consensus of SJU [and conversion to standard
cannabis unit (16)]; (5) programs funding EU-wide research in
the cannabis field; (6) external validation (statistical concept)
of SJU (e.g., indicators) before clinical programs; and (7) data
collection (dose per joint) at the country level. Consideration
of whether it is inappropriate (e.g., normalization of drug-
using behavior and reduced perception of risk) or appropriate
(e.g., reducing stigma and increasing help-seeking) to use the
term “standard” when it comes to a substance that is illegal
in many jurisdictions also arose as relevant point during the
workshop process.
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First Steps
The first three steps (to be implemented concurrently) were:
(1) Set up a “Task Force” that could also act as a lobby for
the European Commission and influence the European Union
(EU) Research Agenda, raising the profile of this subject; (2)
Conduct a review of already available data at the national level;
(3) Emphasize the need for SJU in terms of risks.
DISCUSSION
The 21st century has been characterized as an “Information
Age,” where technologies facilitate the use of information by
citizens. The SJU provides an opportunity to capitalize on this
desire for information by working toward a clear evidence-
based standard which consumers can rely upon. In addition to
leveraging consumer desires for information, the SJU provides
important opportunities for harm reduction and intervention
as the use of cannabis continues to expand in the future. In
fact, although our proposal of establishing a SJU is mainly
focused on regulation of recreational use, it might also be useful
to achieve a better control of those preparations intended for
a potential medical use, which are also generating growing
interest in the last years (31). Given the importance of these
standards for the future of cannabis consumption, the process
of identifying the most efficient and accurate means to develop
the SJU remains a critical task. The results described above
used established expertise across multiple scientific domains to
identify how these standards may be achieved. According to
the expert opinion from the workshop group, the SJU must be
easy-to-use, universal, take into account only the concentration
of THC, and be accurate, and accessible (“easily understood or
appreciated”). With the aim of overcoming the barriers identified
and enhancing the effect of the facilitators, the experts suggested
one main step to be implemented: creating a task force to
emphasize the need for the development of an SJU. This task
force should generate input for the EU Research Agenda and
promote a review of the available data at the national level. The
majority of defining values reported by the participants were also
presented in two recent opinion papers (e.g., assessing only THC,
accessible, universal and easy-to-use) (16, 32). The SJU should
be accurate (defined as “providing a faithful representation of
something”) according to attendees, being different to the SD,
which prioritized utility over accuracy (6). Most of the challenges
discussed [i.e., heterogeneity of routes of administration, laws,
variations over time in THC concentrations (33), compounds
and patterns of use] have also been repeatedly reported as
limitations in previous research (16, 17). Future research must
cope with these barriers by incorporating new methods [e.g.,
trend-spotter method (34), foresight methods (27), participatory
research (35), etc.]. An SJU Task Force should share the necessary
knowledge, skills and expertise in such newmethods. The current
legal status of cannabis in 12 European countries is more flexible
now than it was a few years ago (e.g., incarceration is now not
possible for minor cannabis possession in these 12 countries)
and continues to change (e.g., the government of Luxembourg
is set to provide legal access to cannabis in the near future).
These evolutions in policy could easily open up more research
opportunities in this area (36, 37). Cannabis is high both on
the research and regulatory agenda – a PubMed search using
the terms “marijuana OR marihuana OR cannabis” showed 388
papers in 1998 and 2,190 papers in 2018, thus research interest,
measured by published papers, has increased by 460% within
two decades. Over the same period, the increase of the number
of papers studying “cocaine” was only 8.2%. These patterns
reflect a growing interest in this research area, an interest that
might act as a facilitator for establishing a SJU research agenda,
making it important for researchers to use this momentum to
promote the specific line of research on the SJU. Increased
funding opportunities in Australia, North America, and Europe
are beginning to facilitate much needed research to establish the
SJU. The National Focal Point in Spain for the EMCDDA (Plan
Nacional sobre Drogas) funded two projects related to the SJU.
NIDA also funded research for screening and brief assessment,
development and impact assessment of prevention programs on
marijuana use and patterns and trends in marijuana use and
attitudes (38). These topics are closely related to the development
of an SJU. In 2015, NIDA invested US$ 66M in cannabis research
[> 10% of all research project grants, US$ 625M (39)]. In Europe
several opportunities exist, for example: Supporting Initiatives
in the Field of Drugs Policy (JUST-DRUGS-AG HOME Action
Grant) and European Cooperation in Science and Technology
(40, 41). Recently, NIDA launched a request for information
inviting Comments on the Establishment and Implementation
of a Standard Unit Dose of 1-9-tetrahydrocannabinol (THC)
for Cannabis Research (42). Moreover, the fact that cannabis
is the most widely used psychoactive substance beyond alcohol
and tobacco, with some authors even claiming that there is a
certain normalization of its use, should also stimulate research in
order to overcome the gaps in the specialized literature. Taking
advantage of funding opportunities was critical, according the
expert opinion of participants, in order to enable the creation
of a task force that allows oversight of the available data at
the national levels, and to act as lobbying force to influence
a cannabis research agenda. This network could both facilitate
research and be involved in training relevant workforces in use of
the standard measures.
Limitations and Strengths
The main limitation to our workshop back-casting exercise
was a time constraint (90 minutes vs. 4 or more hours
for other published BCEs), which may have resulted in less
intermediate analyses between description and consensus of
desirable futures (step 1), and back-cast trajectories (step 2) (43).
However, this brief and concentrated version of BCE allows
for the inclusion of a large number of diverse experts who
otherwise would not have been able to attend for timetabling
or financial reasons. Another secondary limitation is the limited
heterogeneity of participants (with few from outside academia).
Fortunately, we think that synergies with other activities in
the LxAddiction2019 Conference will have mitigated these
limitations (e.g., a preconference Workshop on ’International
Cannabis Toolkit’ https://canntoolkit.com/ and a “Big Debate”
session on Day 1 of the conference programme: ’Will changes
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in cannabis policy result in greater costs or greater benefits?’).
The strengths of this BCE exercise were the relevant expertise
in this specific research area of the vast majority of participants;
heterogeneity of research profiles involved (basic science, social
science, epidemiology, neuroimaging, pharmacology, clinical
research) and the inspiring context of the FuturiZe Project and
conference which facilitated creativity and the opportunity for
participants to engage in a co-creative exercise.
CONCLUSIONS
The implementation of a SJU in 2030 was considered feasible
after overcoming several barriers and harnessing contextual
facilitators. Experts agreed that an SJU is possible on the basis
on the following achievements: (1) the building of a task force
to define, develop and advocate for an evidence-based SJU;
(2) reviewing and expanding available national-level data on
cannabis use and related risks; and (3) examining how the SJU
relates to the concept of “risky use” of cannabis.
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